公开(公告)号：US20250051427A1

公开(公告)日：2025-02-13

申请号：US18720518

申请日：2022-11-08

Applicant: EISAI R&D MANAGEMENT CO., LTD. ,  WASHINGTON UNIVERSITY

Inventor： Larisa REYDERMAN ,  Jin ZHOU ,  Lynn KRAMER ,  Michael IRIZARRY ,  Pallavi SACHDEV ,  Shobha DHADDA ,  David LI ,  Kristin WILDSMITH ,  Pau ACEVES BALDO ,  Sumit RAWAL ,  Akihiko KOYAMA ,  Chad SWANSON ,  Michio KANEKIYO ,  June KAPLOW ,  David VERBEL ,  Ishani LANDRY ,  Seiichi HAYATO ,  Robert GORDON ,  Randall BATEMAN ,  Eric MCDADE

IPC: C07K16/18 ,  A61K39/00

Abstract: Disclosed herein are antibodies, pharmaceutical formulations for treating or preventing Alzheimer's disease, methods of treating or preventing Alzheimer's disease, and kits comprising pharmaceutical formulations for treating or preventing Alzheimer's Disease comprising an anti-Aβ protofibril antibody and anti-tau antibody.

公开(公告)号：US20250163135A1

公开(公告)日：2025-05-22

申请号：US18577174

申请日：2022-07-08

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Chad SWANSON ,  Akihiko KOYAMA ,  Michio KANEKIYO ,  Michael IRIZARRY ,  Lynn KRAMER ,  June KAPLOW ,  David VERBEL ,  Shobha DHADDA ,  Pallavi SACHDEV ,  Larisa REYDERMAN ,  Seiichi HAYATO, ,  Ishani LANDRY ,  Robert GORDON

IPC: C07K16/18 ,  A61K39/00 ,  G01N33/68

Abstract: Disclosed herein are method of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.

公开(公告)号：US20240352109A1

公开(公告)日：2024-10-24

申请号：US18688264

申请日：2022-08-29

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Akihiko Koyama ,  Chad Swanson ,  Michio KANEKIYO ,  Michael IRIZARRY ,  Lynn Kramer ,  June KAPLOW ,  David VERBEL ,  Shobha DHADDA ,  Pallavi SACHDEV ,  Larisa REYDERMAN ,  Ishani Landry ,  Seiichi HAYATO ,  Robert Gordon

IPC: C07K16/18 ,  A61K9/00 ,  A61K39/00 ,  A61K47/18 ,  A61K47/26 ,  A61P25/28

CPC classification number: C07K16/18 ,  A61K9/0019 ,  A61K47/183 ,  A61K47/26 ,  A61P25/28 ,  A61K2039/505 ,  A61K2039/545

Abstract: Disclosed herein are methods of treating Alzheimer's disease, methods of reducing clinical decline in a subject having early Alzheimer's disease, methods of reducing brain amyloid level in a subject, methods of converting a subject from amyloid positive to amyloid negative, methods of preventing Alzheimer's disease, the methods comprising subcutaneously administering an anti-Aβ protofibril antibody.